Owlet’s Dream Sock receives Australian medical device certification

LEHI, Utah - Owlet, Inc. (NYSE:OWLT) announced Thursday that its Dream Sock infant monitoring device has received certification from Australia’s Therapeutic Goods Administration (TGA), meeting the medical device standards required in the region.

The Dream Sock, designed for healthy infants between 0-18 months or 2.5-13.6 kg, tracks pulse rate, oxygen level, and sleep patterns. The device transmits real-time readings to the Owlet Dream App, while both the app and included Base Station provide notifications if measurements fall outside preset ranges.

"TGA certification of Dream Sock marks an important step forward in our global expansion, bringing more families worldwide access to the latest pediatric health monitoring technology," said Jonathan Harris, Owlet’s President.

The company plans to make the Dream Sock available for purchase in Australia and New Zealand later this year through its local website and retail partners, including Baby Bunting.

Owlet reports having monitored over two million babies globally with its technology. The company describes itself as a small-cap healthcare growth equity listed on the New York Stock Exchange.

The announcement comes as Owlet continues to expand its presence in international markets. The company’s statement indicates the certification aligns with its strategy to increase global access to its infant monitoring technology.

According to the press release, the Dream Sock is expected to join Owlet’s lineup of FDA-authorized medical and consumer pediatric wearables currently available in other markets.

In other recent news, Owlet Inc. reported its financial results for the second quarter of 2025, highlighting a noteworthy increase in revenue. The company achieved a revenue of $26.1 million, which exceeded the forecasted $20.07 million. However, Owlet’s earnings per share (EPS) fell short of expectations, coming in at -$2.53 compared to the anticipated $0.10. Despite the earnings miss, the revenue growth was a positive surprise for investors. The report led to a significant reaction in the market, reflecting mixed sentiments about the company’s financial performance. Analysts had projected different outcomes, but the actual results highlighted the challenges and opportunities Owlet faces. These developments are part of a series of recent updates regarding Owlet’s financial health and business trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.